Alvotech initiates a pharmacokinetic study for avt03, a proposed biosimilar for prolia® and xgeva®

Reykjavik, iceland, july 20, 2022 (globe newswire) -- alvotech (nasdaq: alvo), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the initiation of a pharmacokinetic study for avt03 (denosumab), a biosimilar candidate to prolia® and xgeva®. the clinical study will assess the pharmacokinetics, safety and tolerability of avt03 compared to prolia® in healthy adult male subjects.
ALVO Ratings Summary
ALVO Quant Ranking